Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

被引：0
|
作者：
Makoto Sudo
Tan Min Chin
Seiichi Mori
Ngan B. Doan
Jonathan W. Said
Makoto Akashi
H. Phillip Koeffler
机构：
[1] National University of Singapore,Cancer Science Institute
[2] National University Hospital,Department of Hematology and Oncology
[3] The Cancer Institute,Department of Cancer Genomics
[4] Japanese Foundation for Cancer Research,Department of Pathology and Laboratory Medicine
[5] University of California,Research Center for Radiation Emergency
[6] National Institute of Radiological Sciences,Division of Hematology and Oncology
[7] Cedars-Sinai Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitor (TKI); EGFR; 17-DMAG; Belinostat; Combination chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1325 / 1334
页数：9
相关论文
共 50 条
  • [41] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [42] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [43] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [44] RETRACTED: miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog (Retracted Article)
    Bi, Mingjun
    Chen, Wei
    Yu, Hongmei
    Wang, Jinxiu
    Ding, Fang
    Tang, Dong Jing
    Tang, Cuiyan
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 480 (03) : 369 - 374
  • [45] The growth inhibitory effect of paclitaxel on gefitinib-resistant non-small cell lung cancer (NSCLC) cells during the COVID-19 pandemic.
    Mohiuddin, Md
    Kimura, Hideharu
    Sone, Takashi
    Watanabe, Satoshi
    Matsuoka, Hiroki
    Saeki, Keigo
    Terada, Nanao
    Abo, Miki
    Kasahara, Kazuo
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [46] Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer
    Yang, Qi
    Chen, Wenyu
    Xu, Yufeng
    Lv, Xiaodong
    Zhang, Ming
    Jiang, Hao
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 356 : 1 - 7
  • [47] Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
    Jeong, Chul-Ho
    Park, Hee Baek
    Jang, Won Jun
    Jung, Su Hyun
    Seo, Young Ho
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 224 - 227
  • [48] Effects of Voltage-gated K+ Channel Blockers in Gefitinib-resistant H460 Non-small Cell Lung Cancer Cells
    Jeon, Won Il
    Ryu, Pan Dong
    Lee, So Yeong
    [J]. ANTICANCER RESEARCH, 2012, 32 (12) : 5279 - 5284
  • [49] Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung
    Ma, Ada T. W.
    Chan, Wai Kong
    Ma, Edmond S. K.
    Cheng, Thomas
    Cheng, Paul N. M.
    [J]. ACTA ONCOLOGICA, 2012, 51 (04) : 557 - U169
  • [50] Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase
    Cao, Lin
    Hong, Weipeng
    Cai, Peiheng
    Xu, Chuncao
    Bai, Xupeng
    Zhao, Zhongxiang
    Huang, Min
    Jin, Jing
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 890
12345